JP2022504392A5 - - Google Patents

Info

Publication number
JP2022504392A5
JP2022504392A5 JP2021518891A JP2021518891A JP2022504392A5 JP 2022504392 A5 JP2022504392 A5 JP 2022504392A5 JP 2021518891 A JP2021518891 A JP 2021518891A JP 2021518891 A JP2021518891 A JP 2021518891A JP 2022504392 A5 JP2022504392 A5 JP 2022504392A5
Authority
JP
Japan
Prior art keywords
antibody fragment
human
domain
met antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518891A
Other languages
English (en)
Japanese (ja)
Other versions
JP7371093B2 (ja
JP2022504392A (ja
Filing date
Publication date
Priority claimed from IT102018000009282A external-priority patent/IT201800009282A1/it
Application filed filed Critical
Publication of JP2022504392A publication Critical patent/JP2022504392A/ja
Publication of JP2022504392A5 publication Critical patent/JP2022504392A5/ja
Application granted granted Critical
Publication of JP7371093B2 publication Critical patent/JP7371093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518891A 2018-10-09 2019-10-07 腫瘍および/または転移の治療のための抗-met fab-fc Active JP7371093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
IT102018000009282 2018-10-09
PCT/EP2019/077116 WO2020074459A1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis

Publications (3)

Publication Number Publication Date
JP2022504392A JP2022504392A (ja) 2022-01-13
JP2022504392A5 true JP2022504392A5 (OSRAM) 2022-05-12
JP7371093B2 JP7371093B2 (ja) 2023-10-30

Family

ID=65010823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518891A Active JP7371093B2 (ja) 2018-10-09 2019-10-07 腫瘍および/または転移の治療のための抗-met fab-fc

Country Status (23)

Country Link
US (2) US12209129B2 (OSRAM)
EP (2) EP4194469A1 (OSRAM)
JP (1) JP7371093B2 (OSRAM)
KR (2) KR102814490B1 (OSRAM)
CN (2) CN113330032B (OSRAM)
AU (2) AU2019358417B2 (OSRAM)
CA (1) CA3115582A1 (OSRAM)
CY (1) CY1125831T1 (OSRAM)
DK (1) DK3864050T5 (OSRAM)
ES (1) ES2938714T3 (OSRAM)
FI (1) FI3864050T3 (OSRAM)
HR (1) HRP20230154T1 (OSRAM)
HU (1) HUE060843T2 (OSRAM)
IL (1) IL282033B2 (OSRAM)
IT (1) IT201800009282A1 (OSRAM)
LT (1) LT3864050T (OSRAM)
PL (1) PL3864050T3 (OSRAM)
PT (1) PT3864050T (OSRAM)
RS (1) RS63960B1 (OSRAM)
SG (1) SG11202103575RA (OSRAM)
SI (1) SI3864050T1 (OSRAM)
SM (1) SMT202300053T1 (OSRAM)
WO (1) WO2020074459A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
WO2026087699A1 (en) 2024-10-24 2026-04-30 Pierre Fabre Medicament New treatment of non-small cell lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309347B2 (en) * 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
BRPI0707480A8 (pt) 2006-02-06 2022-11-08 Vertical Bio Ag Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
EP2013236B1 (en) * 2006-04-28 2015-06-17 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
ES2733067T3 (es) * 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
BRPI1012560A2 (pt) * 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
SI2500036T1 (sl) * 2011-03-18 2014-09-30 Metheresis Translational Research Sa Met inhibitorji za izboljĺ anje uäśinkovitosti obsevanja
AU2012236068A1 (en) * 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
MX2014005885A (es) 2011-11-21 2014-09-04 Genentech Inc Purificacion de anticuerpos anti-c-met.
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CA3050085A1 (en) * 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods

Similar Documents

Publication Publication Date Title
CN115057936B (zh) 异源二聚体多特异性抗体形式
NZ717476A (en) Anti-garp protein and uses thereof
EA032681B1 (ru) ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
DK2921503T3 (en) Human antibody to human epidermal growth factor receptor and coding gene and its use
JP2020536512A (ja) タンパク性ヘテロ二量体及びその使用
JP2023514371A (ja) 操作された抗her2二重特異性タンパク質
JP7792044B2 (ja) ヒト化抗il-1r3抗体及び使用方法
JP7657591B2 (ja) 二重特異性抗原結合コンストラクト
KR20230157933A (ko) 감마-델타 t 세포 수용체에 결합하는 항체
WO2020015687A1 (zh) 抗her3人源化单克隆抗体及其制剂
CN117120478A (zh) 一种抗原结合分子
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
WO2023174238A9 (zh) 特异性结合gprc5d和cd3的抗原结合分子及其医药用途
FI3864050T3 (fi) Anti-met-fab-fc kasvaimen ja/tai metastaasin hoitamiseksi
JP2021518170A5 (OSRAM)
WO2025140701A1 (zh) 抗egfr单抗、其双特异性抗体、药物组合物和用途
WO2020192648A1 (en) Proteinaceous heterodimer and use thereof
WO2024017281A1 (zh) 多特异性抗体及其用途
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
JP2024534824A (ja) 操作された抗her2二重特異性タンパク質
US20230391892A1 (en) Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof
HK40110414A (zh) 抗her2抗体及其使用方法
HK40084724A (en) Engineered anti-her2 bispecific proteins
WO2024188319A1 (zh) 抗muc17、cd3和cd28三特异性抗体
WO2024131849A1 (zh) Cd38单克隆抗体及其应用